7OXN image
Entry Detail
PDB ID:
7OXN
Keywords:
Title:
Crystal Structure of TAP01 in complex with cyclised amyloid beta peptide
Biological Source:
Source Organism:
Host Organism:
PDB Version:
Deposition Date:
2021-06-22
Release Date:
2022-06-29
Method Details:
Experimental Method:
Resolution:
2.50 Å
R-Value Free:
0.26
R-Value Work:
0.22
Space Group:
I 1 2 1
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Amyloid-beta precursor protein
Chain IDs:C (auth: A)
Chain Length:14
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:TAP01 family antibody heavy chain
Chain IDs:A (auth: H)
Chain Length:219
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:TAP01 family antibody light chain
Chain IDs:B (auth: K)
Chain Length:214
Number of Molecules:1
Biological Source:Homo sapiens
Primary Citation
Discovery of a novel pseudo beta-hairpin structure of N-truncated amyloid-beta for use as a vaccine against Alzheimer's disease.
Mol Psychiatry 27 840 848 (2022)
PMID: 34776512 DOI: 10.1038/s41380-021-01385-7

Abstact

One of the hallmarks of Alzheimer's disease (AD) are deposits of amyloid-beta (Aβ) protein in amyloid plaques in the brain. The Aβ peptide exists in several forms, including full-length Aβ1-42 and Aβ1-40 - and the N-truncated species, pyroglutamate Aβ3-42 and Aβ4-42, which appear to play a major role in neurodegeneration. We previously identified a murine antibody (TAP01), which binds specifically to soluble, non-plaque N-truncated Aβ species. By solving crystal structures for TAP01 family antibodies bound to pyroglutamate Aβ3-14, we identified a novel pseudo β-hairpin structure in the N-terminal region of Aβ and show that this underpins its unique binding properties. We engineered a stabilised cyclic form of Aβ1-14 (N-Truncated Amyloid Peptide AntibodieS; the 'TAPAS' vaccine) and showed that this adopts the same 3-dimensional conformation as the native sequence when bound to TAP01. Active immunisation of two mouse models of AD with the TAPAS vaccine led to a striking reduction in amyloid-plaque formation, a rescue of brain glucose metabolism, a stabilisation in neuron loss, and a rescue of memory deficiencies. Treating both models with the humanised version of the TAP01 antibody had similar positive effects. Here we report the discovery of a unique conformational epitope in the N-terminal region of Aβ, which offers new routes for active and passive immunisation against AD.

Legend

Protein

Chemical

Disease

Primary Citation of related structures